Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

每经记者｜肖纯 每经编辑｜刘艳美 各地高考成绩陆续公布，即将进入志愿填报时间。 就在近日，两所新型研究型大学——宁波东方理工大学、大湾区大学同时获教育部批复，将于今年开始招收首批本科生。 近年来，多所新型研究型大学相继成立或筹划建设。除上述两所大学外，上海科技大学、西湖大学、南方科技大学、深圳理工大学等均已开始招生，福耀科 技大学同样于今年获批成立，钱塘大学也在加快推进。 这些年轻大学的办学定位，几乎都聚焦高起点、小而精、研究型、国际化等关键词，不仅硬件一流，而且纷纷请来大师、院士坐镇。而在这些大学的愿景 中，斯坦福、麻省理工学院、加州理工学院等顶尖名校，常被视为"对标"对象。 对广大考生和家长来说，报志愿是一道重要性不亚于高考本身的"大题"。一张志愿，实际包括城市、大学、专业三个选择。而这三个选择，正好可以作为观 察这批新型研究型大学的三个维度。 以今年即将开始招生的三所新学校为例。以城市的维度来看，三所大学全部位于经济发达的东南沿海地区，宁波、东莞、福州都是GDP超万亿、产业基础 好，且都缺乏优质教育资源的城市。 图片来源："东方理工"官方微信号 宁波东方理工大学由韦尔股份董事长虞仁荣斥资创办。该校202 ...

Core Insights - Hoth Therapeutics' investigational candidate HT-001 achieved a 100% response rate in at least one primary efficacy endpoint in its ongoing Phase 2a clinical study for EGFR inhibitor-induced skin toxicities [2][7] - The company will host a Key Opinion Leader event to discuss the interim results and potential impact of HT-001 on supportive care standards for oncology patients [1] Clinical Trial Highlights - The Phase 2a trial (CLEER-001) demonstrated that 100% of enrolled patients achieved at least one primary endpoint of clinical dermatologic improvement [7][8] - Over 65% of patients reported reductions in pain and pruritus, with 0% requiring dose reduction or discontinuation of their EGFR inhibitor therapy [7][8] - HT-001 is a once-daily topical gel that targets neuroinflammatory pathways without causing immunosuppression or systemic toxicity [4] Mechanism of Action - HT-001 is formulated with an FDA-approved neurokinin-1 receptor antagonist (NK1RA) that mitigates inflammatory pathways triggered by EGFR inhibition, particularly those driven by Substance P [4][5] - Preclinical data showed significant reductions in dermatitis and alopecia severity, as well as inflammatory markers in rat models co-treated with erlotinib [5][9] Regulatory and Development Pathway - HT-001 is being advanced under the 505(b)(2) regulatory pathway, which allows the use of existing safety data to expedite development [10] - The company is currently planning a Phase 2b/3 trial following the ongoing Phase 2a trial [13]

Group 1 - Mastercard is well-positioned to handle potential disruptions from stablecoins, with limited immediate threats to its core business despite major retailers considering their own stablecoins [1][8] - Stablecoins offer benefits like faster settlement and lower transaction costs, but lack consumer advantages such as credit access, fraud protection, and rewards, where Mastercard excels [2][8] - Mastercard is actively innovating by introducing initiatives like the Multi-Token Network and piloting USDC settlements to integrate blockchain technology into its payment systems [3][8] Group 2 - Historical technological shifts, such as mobile wallets, have complemented traditional card networks, suggesting a similar outcome may occur with stablecoins [4] - There are potential revenue risks if merchant-led stablecoin platforms gain traction faster than expected, particularly in high-fee or cross-border segments [4][5] - Overall, Mastercard's proactive innovation strategy and established consumer advantages indicate a likelihood of adapting and thriving alongside emerging technologies [5] Group 3 - Mastercard shares have increased by 3% year to date, outperforming the broader industry's decline of 0.1% [7] - The company trades at a forward price-to-earnings ratio of 31.42X, which is higher than the industry average, and carries a Value Score of D [10] - The Zacks Consensus Estimate predicts a 9.5% rise in Mastercard's fiscal 2025 earnings year over year, followed by a 16.7% growth in the subsequent year [11]

Core Business Performance - Abbott is experiencing increased global demand for routine diagnostic tests, particularly in its Diagnostics business, which accounted for 20% of total revenues in Q1 2025 [3][4] - The Diabetes Care segment is benefiting from strong sales of the FreeStyle Libre continuous glucose monitoring system, with Q1 sales exceeding $1.7 billion and growing 21.6% [5][8] - Established Pharmaceuticals (EPD) sales rose 8% organically in Q1 2025, with significant growth in emerging markets and a focus on biosimilars [10][8] Market Position and Financials - Abbott's market capitalization stands at $231.38 billion, with an earnings yield of 3.9%, significantly higher than the industry's 0.5% [2] - The company has outperformed earnings estimates in three of the last four quarters, achieving an average earnings surprise of 1.6% [2] - The Zacks Consensus Estimate for Abbott's 2025 revenues is projected at $44.68 billion, indicating a 6.5% increase from the previous year [13] Strategic Initiatives - Abbott is investing $0.5 billion in new manufacturing and R&D facilities in Illinois and Texas to enhance its U.S. transfusion diagnostics business [4] - The launch of the Alinity m system will allow Abbott to enter the molecular nucleic acid testing market, which is valued at $1 billion [4] - Abbott has secured rights to 15 biosimilar products, positioning itself for growth in the branded generic pharmaceutical market [10][9] Challenges and Risks - Macroeconomic pressures, including geopolitical tensions and rising raw material costs, are expected to impact Abbott's margins and sales [11][12] - Foreign exchange fluctuations have negatively affected Abbott's international sales, with a 2.8% unfavorable year-over-year impact reported in Q1 2025 [12]

Core Viewpoint - Banco De Chile (BCH) has experienced significant selling pressure, resulting in a 6.2% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if BCH is oversold, with a reading of 28.33 indicating potential exhaustion of selling pressure [2][5] - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify potential price reversals, suggesting that BCH may present entry opportunities for investors [3] Group 2: Fundamental Analysis - Analysts have raised earnings estimates for BCH by 3.6% over the last 30 days, indicating a positive trend that typically correlates with price appreciation [7] - BCH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, further supporting the potential for a near-term turnaround [8]

Core Viewpoint - Skillsoft Corp. (SKIL) has experienced significant selling pressure, resulting in a 30.2% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating a potential turnaround for the stock [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - SKIL's current RSI reading is 28.35, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for SKIL, leading to a 52.8% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7]. Group 3: Analyst Ratings - SKIL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Group 1 - ASML has reached a significant support level and is considered a good pick for investors from a technical perspective, having recently broken through the 20-day moving average, indicating a short-term bullish trend [1] - The 20-day simple moving average (SMA) is a popular investing tool that helps smooth out price fluctuations and can show more trend reversal signals than longer-term moving averages [2] - ASML shares have increased by 6.5% over the past four weeks, and the company holds a Zacks Rank 2 (Buy), suggesting potential for continued growth [4] Group 2 - Positive earnings estimate revisions further strengthen the bullish case for ASML, with no earnings estimates lowered in the past two months and two raised estimates for the current fiscal year, leading to an increase in the consensus estimate [4] - Investors are encouraged to consider adding ASML to their watchlist due to the important technical indicator and the positive movement in earnings estimate revisions [5]

Core Viewpoint - Iamgold (IAG) has reached a significant support level and shows potential for investors from a technical perspective, particularly after breaking through the 20-day moving average, indicating a short-term bullish trend [1]. Technical Analysis - The 20-day simple moving average (SMA) is a widely used investing tool that helps smooth out price fluctuations and provides insight into short-term price trends [1][2]. - A stock price moving above the 20-day SMA is considered a positive trend, while falling below it signals a downward trend [2]. Performance Metrics - IAG shares have increased by 13.4% over the past four weeks, indicating a positive momentum [4]. - The company currently holds a Zacks Rank of 3 (Hold), suggesting potential for continued growth [4]. Earnings Estimates - Positive revisions in earnings estimates bolster the bullish outlook for IAG, with no estimates lowered in the past two months and three raised estimates for the current fiscal year [4]. - The consensus earnings estimate has also seen an increase, further supporting the positive sentiment around IAG [4]. Investment Consideration - Given the important technical indicators and the positive movement in earnings estimate revisions, IAG should be considered for investors' watchlists [5].

Tim Scoffham Tim Scoffham, CEO of Sports.com Media LTD and Lottery.com International LTD. FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (NASDAQ: LTRY, LTRYW) (“Lottery.com” or “the Company”), a leading technology company transforming the intersection of gaming, sports and entertainment, today announced the appointment of Tim Scoffham as Chief Executive Officer of Sports.com Media Group Limited (“Sports.com Media”) and Lottery.com International Limited (“Lottery.com International” ...